MannKind Expands Commercial Scale Manufacturing Capabilities for High-Potency Molecules
July 11 2019 - 4:14PM
MannKind Corporation
(Nasdaq:MNKD), a company focused on the
development and commercialization of inhaled therapeutic products
for patients with diseases such as diabetes and pulmonary arterial
hypertension, announced that it has completed construction of a new
high-potency manufacturing suite in its Danbury Connecticut
facility. This expansion provides the Company with the
capability to produce dry powder formulations of highly potent
active ingredients, such as epinephrine, on a commercial scale, in
alignment with MannKind's strategic partnerships. The new suite
will house bulk powder formulation and fill/pack operations for
high-potency powders and adds to MannKind's extensive commercial
manufacturing capability, which includes inhalation devices,
large-scale compounding, particle formation, tangential flow
filtration, cryogranulation, and high capacity (300 kg/day)
lyophilization.
“This expansion will allow us to utilize more
fully the capacity of our world class, FDA-approved manufacturing
facility for dry powder inhalation products. We are also
pursuing opportunities to utilize our lyophilization capacity to
fulfill the needs of our industry and drug development partners,"
stated Joe Kocinsky, Chief Technology Officer of MannKind.
About MannKind Corporation MannKind
Corporation (NASDAQ:MNKD) focuses on the development and
commercialization of inhaled therapeutic products for patients with
diseases such as diabetes and pulmonary arterial
hypertension. MannKind is currently commercializing
Afrezza® (insulin human) Inhalation Powder, the Company's
first FDA approved product and the only inhaled rapid-acting
mealtime insulin in the United States, where it is
available by prescription from pharmacies
nationwide. MannKind is headquartered in Westlake
Village, California, and has a state-of-the art manufacturing
facility in Danbury, Connecticut. The Company also
employs field sales and medical representatives across the U.S. For
further information, visit www.mannkindcorp.com.
MannKind Contact:
Rose Alinaya Investor Relations 818-661-5000
ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Aug 2024 to Sep 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Sep 2023 to Sep 2024